Carlsbad-based Isis Pharmaceuticals Inc. (Nasdaq: ISIS) has initiated a Phase 1 clinical study for an anti-sense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease.
ISIS-ANGPTL3Rx is designed to act as a broad dyslipidemia agent and has the potential to reduce LDL-cholesterol and triglycerides, to increase insulin sensitivity.
Isis plans to evaluate ISIS-ANGPTL3Rx in patients who have severe metabolic or cardiovascular disease and who would benefit from a drug that simultaneously addresses a variety of adverse lipid and metabolic parameters contributing to their disease.
The Phase 1 study of ISIS-ANGPTL3Rx is a blind, placebo-controlled, dose-escalation study in approximately 48 healthy volunteers. The study is designed to assess the safety, tolerability and pharmacokinetics of both single and multiple doses of ISIS-ANGTPL3Rx.
1896 Rutherford Road
Carlsbad, CA 92008